Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead

Continued uptake of Biktarvy helps offset declines for other products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead

4Q Revenues: $5.9 billion (flat)

4Q Earnings: $2.7 billion (nm)   

FY Revenues: $22.4 billion (+1%)

FY Earnings: $5.4 billion (-2%)

Comments: Product sales for the fourth quarter of 2019 were $4.5 billion in the United States, $840 million in Europe and $440 million in other locations. HIV product sales were $4.6 billion in the quarter, up 12% primarily driven by higher sales volume as a result of the continued uptake of Biktarvy. Chronic hepatitis C virus (HCV) product sales were $630 million for the fourth quarter, down 15%. Yescarta generated $122 million in sales during the quarter, compared to $81 million in 4Q18. Other product sales, which include products from chronic hepatitis B virus (HBV), cardiovascular, oncology and other categories, inclusive of Vemlidy, Viread, Letairis, Ranexa, Zydelig, AmBisome and Cayston, were $467 million for the quarter compared to $797 million for the same period in 2018. The decreases were primarily due to declines in Ranexa and Letairis sales after generic entries in 2019.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters